Crenolanib For Treating Flt3 Mutated Proliferative Disorders

Patent No. EP2941251 (titled "Crenolanib For Treating Flt3 Mutated Proliferative Disorders") was filed by Arog Pharmaceuticals on Oct 14, 2013. The application was issued on Mar 7, 2018.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
HEXAL PHARMADec 7, 2018KRAUS & LEDERER
HEXAL PHARMADec 7, 2018KRAUS & LEDERER PARTGMBB

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP2941251

AROG PHARMACEUTICALS
Application Number
EP13869984A
Filing Date
Oct 14, 2013
Status
Opposition Rejected
May 9, 2025
Publication Date
Mar 7, 2018